期刊文献+

丹参桃芎汤对肝纤维化小鼠腹膜淋巴孔的调控与尿钠离子浓度变化的影响 被引量:9

Experimental Study on Effect of Danshen Tao Xiong Decoction on the Peritoneal Lymphatic Stomata and Urinary Sodium in Hepatic Fibrosis Mice
暂未订购
导出
摘要 目的:寻找治疗肝硬变腹水的有效方药。方法:具有腹膜淋巴孔调控作用的丹参配合活血化瘀的桃仁、川芎组成丹参桃芎汤对肝纤维化造模小鼠进行腹膜淋巴孔调控与尿离子浓度变化的实验,并经扫描电镜和计算机图像处理与定量分析。结果:预防组、治疗组腹膜淋巴孔孔径、密度与模型组、对照组比较;有非常显著性差异(P<0.001),而尿离子测定,治疗组不及预防组。结论:丹参桃芎汤是治疗腹水的有效方剂。 Aim: To find effective drug treating hepatic fibrosis ascites. Methods: Danshen Tao Xiong Decoction (DSTXU) Composed of Radix Salviae Miltiorrhizae has effect on the regulation of the peritoneal lymphatic stomata, Semen Persicae and Rhizoma Ligustici Chuanxiong providing with promoting blood circulation to remove blood stasis, was used in the research of the peritoneal lymphatic stomata and urinary sodium in hepatic fibrosis mice. The diameter and distributive density of the peritoneal lymphatic stomata were quantitatively analysed by using scanning electron microscope and computer image system. Results :The diameter and distributive density were more obvious in prevention and treatment groups than the control and model groups. Urinary sodium in prevention group drain more than that in treatment group. Conclusion: DSTXD is an effective formula for the treatment of ascites.
出处 《中西医结合肝病杂志》 CAS 2000年第1期22-23,共2页 Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases
基金 国家中医药管理局重点项目(NO.97Z031) 浙江省中医管理局重点基金 卫生部优秀青年人才专项基金 浙江省分析测试基金
关键词 腹膜淋巴孔 肝纤维化 丹参桃芎渗 尿钠离子 Peritoneal Lymphatic Stomata Hepatic Fibrosis Danshen Tao Xiong Decoction Urinary Sodium
  • 相关文献

参考文献4

二级参考文献69

  • 1Verkerk A J, Pieretti M, Sutcliffe JS, et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Ce11,1991,65:905-914.
  • 2Wittenberger MD, Hagerman RJ, Sherman SL, et al. The FMR1 premutation and reproduction. Fertil Steri|, 2007,87:456-465.
  • 3Allingham-Hawkins DJ, Babul-Hirji R, Chitayat D, et al. Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in Fragile X study-- preliminary data. Am J Med Genet, 1999,83:322-325.
  • 4Sullivan AK, Marcus M, Epstein MP, et al. Association of FMR1 repeat size with ovarian dysfunction. Hum Reprod,2005 ,20 :402- 412.
  • 5Bodega B, Bione S, Dalpra L, et al. Influence of intermediate and uninterrupted FMR1 CGG expansions in premature ovarian failure manifestation. Hum Reprod, 2006,21:952-957.
  • 6Bretherick KL, Fluker MR, Robinson WP. FMR1 repeat sizes in the gray zone and high end of the normal range are associated with premature ovarian failure. Hum Genet, 2005,117:376-382.
  • 7Gleicher N, Weghofer A, Barad DH. A pilot study of premature ovarian senescence: I. Correlation of triple CGG repeats on the FMR1 gene to ovarian reserve parameters FSH and anti-Mtillerian hormone. Fertil Steril,2009,91:1700-1706.
  • 8Fu YH, Kuhl DP, Pizzuti A, et al. Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell, 1991,67 : 1047-1058.
  • 9Murray A, Ennis S, MacSwiney F, et al. Reproductive and menstrual history of females with fragile X expansions. Eur J Hum Genet, 2000,8:247-252.
  • 10Chatterjee S, Maitra A, Kadam S, et al. CGG repeat sizing in the FMR1 gene in Indian women with premature ovarian failure. Reprod Biomed Online ,2009,19:281-286.

共引文献29

同被引文献51

引证文献9

二级引证文献71

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部